Y Intercept Hong Kong Ltd Has $415,000 Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Y Intercept Hong Kong Ltd lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 96.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,185 shares of the life sciences company’s stock after selling 76,094 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Illumina were worth $415,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC raised its stake in Illumina by 23.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,755 shares of the life sciences company’s stock worth $1,018,000 after buying an additional 1,831 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Illumina by 3.6% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 399,966 shares of the life sciences company’s stock valued at $41,748,000 after purchasing an additional 13,725 shares in the last quarter. Fifth Third Bancorp grew its position in shares of Illumina by 13.6% in the 2nd quarter. Fifth Third Bancorp now owns 5,870 shares of the life sciences company’s stock valued at $613,000 after purchasing an additional 704 shares during the period. Louisiana State Employees Retirement System increased its stake in Illumina by 166.4% during the 2nd quarter. Louisiana State Employees Retirement System now owns 57,800 shares of the life sciences company’s stock worth $6,033,000 after purchasing an additional 36,100 shares in the last quarter. Finally, New York State Teachers Retirement System raised its holdings in Illumina by 8.4% during the 2nd quarter. New York State Teachers Retirement System now owns 155,323 shares of the life sciences company’s stock worth $16,213,000 after buying an additional 12,054 shares during the period. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on ILMN shares. Canaccord Genuity Group upped their price target on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a report on Tuesday, November 5th. Piper Sandler lowered their target price on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Wednesday, August 28th. Morgan Stanley reiterated an “equal weight” rating and set a $156.00 price objective on shares of Illumina in a report on Tuesday, November 12th. Finally, UBS Group boosted their target price on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $165.95.

Illumina Stock Performance

ILMN opened at $144.40 on Tuesday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 12-month low of $100.08 and a 12-month high of $156.66. The business has a 50 day moving average of $144.35 and a 200-day moving average of $128.93. The stock has a market cap of $22.90 billion, a price-to-earnings ratio of -14.50 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.33 earnings per share. On average, equities research analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.